Overview
- Describes potential novel drug targets for age-related disorders
- Reviews studies and current research on age-related disorders worldwide
- Discusses developments for new therapeutic approaches to age-related disorders
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1286)
Part of the book sub series: Proteomics, Metabolomics, Interactomics and Systems Biology (PMISB)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (17 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
Aging is an inevitable part of life, and is becoming a worldwide social, economic and health problem due to the fact that an increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders. New therapeutic approaches are still in need to decrease or slow the effects of such diseases in this aging society. Advances in ‘omic technologies such as genomics, transcriptomics, proteomics and metabolomics have significantly advanced our understanding of diseases in multiple medical areas. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan, which will in turn lead to new therapeutic strategies and drug development projects by the pharmaceutical industry. This new book presents a series of reviews describing studies which have resulted in the identification of potential new drug targets for age-related disorders. Much of this information has come from ‘omic comparisons of healthy and disease states or from testing the effects of potential new therapeutic approaches. Each chapter will be presented in the context of specific chronic diseases or different therapeutic strategies, providing important information on disease mechanisms related to the aging process. This book will be of interest to researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians, and major drug companies. With contributors from Australia, Brazil, Canada, France, Germany, India, Iran, Iraq, South Africa, South Korea, Thailand, Ukraine, United Kingdom, United States of America, Uruguay and Vietnam, this is a timely follow up to Guest’s previous book Reviews on New Drug Targets in Age-Related Disorders.
Editors and Affiliations
About the editor
​Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 37 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer’s disease, and more recently in the area of anti-aging research.
Bibliographic Information
Book Title: Reviews on New Drug Targets in Age-Related Disorders
Book Subtitle: Part II
Editors: Paul C. Guest
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-030-55035-6
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021
Hardcover ISBN: 978-3-030-55034-9Published: 17 March 2021
eBook ISBN: 978-3-030-55035-6Published: 16 March 2021
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: VIII, 272
Number of Illustrations: 10 b/w illustrations, 31 illustrations in colour
Topics: Bioinformatics, Genetics and Genomics, Biochemistry, general